Traditional complexities of molecular PCR testing have limited its use to specialized laboratories. Xpert Flu A Panel is the first molecular test authorized for use in “moderate complexity” laboratories, extending testing access to the hospital near-patient setting.

Xpert^® Flu A Panel* delivers.

*EUA: Emergency Use Authorization

Runs On: GeneXpert^® System

The Need

2009 H1N1 has been reported as the predominant flu strain during the 2009–2010 flu season. Because this is a new flu virus most people do not have immunity to it and disease may be more severe and widespread as a result:

• Since April 2009, the 2009 H1N1 flu virus has sickened an estimated 22 million Americans, hospitalized about 98,000 and killed 3,900
• Current available rapid diagnostic tests exhibit limited sensitivity (10–70%) compared to real-time PCR for detection of 2009 H1N1, and are unable to discriminate influenza strain type
• Laboratories are experiencing an unprecedented increase in test requests for respiratory influenza — including specific requests for identification of 2009 H1N1 via PCR. In many cases these requests can only be processed as send-outs with lengthy results reporting that minimize the medical value of the tests
  

The Solution

Rapid determination of Flu A infection and the identification of 2009 H1N1 can assist clinicians in making real-time medical decisions during patient presentation:

• Rapid identification of infection improves isolation and infection control measures and enhances patient flow and bed utilization
• Detection of Flu A infection and the identification of 2009 H1N1 influenza strain reduces need for additional or confirmatory testing
• Xpert Flu A Panel is authorized for use in laboratories performing “moderate complexity” testing
• Less than two minutes hands-on time improves lab workflow efficiencies
• Innovative single-use cartridge design enables on-demand STAT Testing